loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Ozogamicin

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Ozogamicin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    The top 10 antibody drug conjugate contenders in 2021
    The top 10 antibody drug conjugate contenders in 2021

    13 Sep 2021

    // FIERCEPHARMA

    https://www.fiercepharma.com/special-report/top-10-antibody-drug-conjugate-contenders-2021

    FIERCEPHARMA
    13 Sep 2021
    Share Share
    Wyeth’s Mylotarg (Gemtuzumab Ozogamicin) Receives Supplemental Approval In US
    Wyeth’s Mylotarg (Gemtuzumab Ozogamicin) Receives Supplemental Approval In US

    29 Feb 2020

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761060

    FDA
    29 Feb 2020
    Share Share
    Wyeth Pharm’s Mylotarg (Gemtuzumab Ozogamicin) Receives Supplemental Approval In US
    Wyeth Pharm’s Mylotarg (Gemtuzumab Ozogamicin) Receives Supplemental Approval In US

    12 Apr 2018

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761060

    FDA
    12 Apr 2018
    Share Share
    NICE set to reject Pfizer's leukaemia drug Besponsa
    NICE set to reject Pfizer's leukaemia drug Besponsa

    22 Aug 2017

    // Gemma Jones PMLIVE

    http://www.pmlive.com/pharma_news/nice_set_to_reject_pfizers_leukaemia_drug_besponsa_1202669

    Gemma Jones PMLIVE
    22 Aug 2017
    Share Share
    Wyeth Pharm’s Inotuzumab Ozogamicin Receives Supplemental Approval In US
    Wyeth Pharm’s Inotuzumab Ozogamicin Receives Supplemental Approval In US

    18 Aug 2017

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761040

    FDA
    18 Aug 2017
    Share Share
    FDA accepts Pfizer’s blood cancer candidate for speedy review
    FDA accepts Pfizer’s blood cancer candidate for speedy review

    21 Feb 2017

    // Ben Adams FIERCE BIOTECH

    http://www.fiercebiotech.com/biotech/fda-accepts-pfizer-s-blood-cancer-candidate-for-speedy-review

    Ben Adams FIERCE BIOTECH
    21 Feb 2017
    Share Share